Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
Tokyo-based health tech CureApp earned Japanese regulatory approval for its digital therapeutic app for hypertension, President Kota Satake revealed on April 27. The company is now looking at its health coverage and rollout during this year. The app, which was…
To read the full story
Related Article
- Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
September 6, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…